Release date: 2017-10-24
New immunotherapy can enhance the body's immune defense against cancer cells, and treatment of patients with advanced disease often promotes part of the patient's body tumors, and even all tumor recurrence, but such strategies often fail in the treatment of advanced cancer patients. The end, but the mechanism behind the researchers is not clear; recently, researchers from the University of Magdeburg and the University Hospital of Bonn have discovered through research that a mechanism has not been identified before. Can limit the efficiency of cancer immunotherapy, the results of the study published in the international magazine Immunity, the research may provide new ideas and mechanisms for the development of new cancer immunotherapy for later researchers.
Under normal circumstances, T lymphocytes in the immune system can detect and destroy viruses and bacteria, and it can also eliminate cancer cells that have mutations. New treatments based on immune checkpoint inhibitors can adjust cellular immunity and enhance immunity. The system recognizes and kills cancer cells. This new treatment is often used to treat patients with malignant melanoma. Recently, this treatment has also been used to treat other solid tumor patients, and has achieved certain results. However, in many cancer patients, immunotherapy often does not or only shows temporary therapeutic effects, and researchers around the world are now trying to understand the mechanisms behind them.
In this study, the researcher Michael Holzel and others discovered a new mechanism that can limit cancer immunotherapy. The researchers observed the important role of neutrophils, a kind of neutrophil in the blood. Common immune cells, which can act as the body's first immune defense against foreign invading pathogens, can also attack cancer cells; however, in a cancer mouse model, researchers have found that neutrophils can suppress T lymphocytes. Activity, thereby attenuating the therapeutic effects of immunotherapy.
Researcher Nicole Glodde said that we found that a soluble mediator released by cancer tissue when attacking T lymphocytes can trigger unexpected changes in neutrophil characteristics, which researchers believe may be soluble. Being able to reveal the "dark" side of neutrophils, like Dr. Jekyll of goodness, becomes a ruthless Hyde teacher when taking special medicines; researchers speculate that this mechanism can normally protect The body resists excessive inflammatory reactions, but in the case of immunotherapy, this may be quite unlucky.
In addition, the researchers also clarified how to suppress the unfortunate transformation of neutrophils. This study may provide some theoretical support for further investigation and clinical trials in the later period, helping researchers to develop more effective new individualized cancer immunotherapy in the future.
Source: Bio Valley
-86C Freezer
86C Freezer,Low Temp Vaccine Storage Fridge,Lab Low Temp Vaccine Storage,Low Temperature Deep Freezer
Guangdong Widinlsa International Co.Ltd , https://www.gdwidinlsa.com